Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 18/20 | 0.38 |
| ▸ | PSEN2 | P49810 | 18/20 | 0.38 |
| ▸ | APH1B | Q8WW43 | 18/20 | 0.38 |
| ▸ | NCSTN | Q92542 | 18/20 | 0.38 |
| ▸ | APH1A | Q96BI3 | 18/20 | 0.38 |
| ▸ | PSENEN | Q9NZ42 | 18/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | CASP3 | P42574 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | RELA | Q04206 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13314774 | 1.00 | PSEN1 (0.38) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| Formic Acid SCHEMBL3536180 | 0.95 | PSEN1 (0.35) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3536181 | 0.83 | PSEN1 (0.32) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3537650 | 0.79 | PSEN1 (0.59) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3535415 | 0.75 | NPC1 (0.35) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL13314780 | 0.75 | NPC1 (0.35) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| Formic Acid SCHEMBL3537253 | 0.74 | PSEN1 (0.54) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3986941 | 0.73 | — | — | |
| SCHEMBL3536165 | 0.73 | NPC1 (0.34) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3536663 | 0.73 | NPC1 (0.34) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7727979-B2 | Guanidine derivatives and their use as neuropeptide FF receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-06-01 | — | — | US | claimed |
| US-20060194788-A1 | Guanidine derivatives and their use as neuropeptide ff receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2006-08-31 | — | — | US | claimed |
| US-20150246140-A1 | COMPOSITIONS AND METHODS FOR MODULATING SLEEP AND WAKEFULNESS | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2015-09-03 | — | — | US | disclosed |
| WO-2015120446-A1 | COMPOSITIONS AND METHODS FOR MODULATING SLEEP AND WAKEFULENESS | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2015-08-13 | — | — | WO | disclosed |
| US-7727979-B2 | Guanidine derivatives and their use as neuropeptide FF receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-06-01 | — | — | US | disclosed |
| US-20060194788-A1 | Guanidine derivatives and their use as neuropeptide ff receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2006-08-31 | — | — | US | disclosed |
| EP-1608662-A1 | GUANIDINE DERIVATIVES AND USE THEREOF AS NEUROPEPTIDE FF RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2005-12-28 | — | — | EP | disclosed |
| WO-2004083218-A1 | GUANIDINE DERIVATIVES AND USE THEREOF AS NEUROPEPTIDE FF RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2004-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194788-A1 | Guanidine derivatives and their use as neuropeptide ff receptor antagonists | NPFFR1, OGFR, NPFFR2 | PSEN1 2771/4885PSEN2 2831/4885APH1B 3981/4885 |
| US-20150246140-A1 | COMPOSITIONS AND METHODS FOR MODULATING SLEEP AND WAKEFULNESS | HCRTR2, HCRTR1, NPSR1 | PSEN1 819/4885PSEN2 648/4885APH1B 1346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.